Group 1 - The stock price of Sichuan Shuangma closed at 19.33 yuan on August 4, 2025, with a slight decrease of 0.02 yuan, representing a drop of 0.10% [1] - The company reported a trading volume of 1.58 billion yuan, with a fluctuation of 1.91% and a turnover rate of 1.08% on the same day [1] - Sichuan Shuangma's main business includes cement and building materials, while also venturing into biotechnology and medical aesthetics [1] Group 2 - The company aims to continuously promote the development of its core business and focus on high-growth industries such as biotechnology [1] - Sichuan Shuangma is seeking synergistic business opportunities to enhance its long-term competitiveness [1] - In investor interactions, the company expressed its commitment to optimizing its business layout and enhancing investor confidence through performance growth and development prospects [1] Group 3 - On August 4, the net inflow of main funds was 3.6693 million yuan, with a cumulative net inflow of 22.8371 million yuan over the past five days [1]

Summary of Key Points Core Viewpoint - The Hong Kong Stock Exchange (HKEX) reported that seven companies submitted applications for listing, with two companies passing the hearing and one company currently in the process of an initial public offering (IPO) without any new stocks listed during the week. Group 1: Companies Submitting Applications - **Wenzhi Traditional Chinese Medicine**: The largest AI-assisted TCM service provider in mainland China, with projected revenues of approximately 621.69 million RMB in 2022 and a loss of about 154 million RMB in the same year [2] - **Zhengpin Holdings Limited**: Engaged in the development and distribution of health and beauty supplements in Hong Kong, with revenues projected to reach approximately 110 million HKD in 2025 and a profit of about 35.5 million HKD in the same year [3] - **YunTian LiFei Technology Co., Ltd.**: A leading AI company focusing on AI inference chips, with revenues expected to be around 5.46 billion RMB in 2022 and a loss of approximately 4.47 billion RMB [4] - **Xinnengda Electronics Co., Ltd.**: A global leader in lithium battery technology, with projected revenues of about 521.62 billion RMB in 2022 and a profit of approximately 7.63 billion RMB [5] - **Danno Pharmaceutical (Suzhou) Co., Ltd.**: A biotech company focused on innovative drug development, with losses projected to be around 1.22 billion RMB in 2023 [6] - **Innovation International Industrial Group**: Engaged in the production of aluminum products, with revenues expected to reach approximately 134.90 billion RMB in 2022 and a profit of about 9.13 billion RMB [7] - **Wangshan Wangshui Biopharmaceutical Co., Ltd.**: Focused on small molecule drug development, with revenues projected to be around 200 million RMB in 2023 [8] Group 2: Companies Passing Hearings - **Shandong Tianyue Advanced Technology Co., Ltd.**: A leading manufacturer of silicon carbide substrates, with revenues projected to be approximately 4.17 billion RMB in 2022 and a loss of about 1.76 billion RMB [8] - **Guangzhou Yinnuo Pharmaceutical Group Co., Ltd.**: Focused on innovative drug development for metabolic disorders, with no recorded revenue in 2023 and a loss of approximately 733 million RMB [9] Group 3: IPO and Market Updates - **Zhonghui Biotechnology-B**: Plans to offer 33.44 million H-shares with a price range of 12.9 to 15.5 HKD per share, aiming for a total of approximately 1.02 billion HKD from cornerstone investors [10] - **HKEX New IPO Regulations**: New rules effective from August 4 aim to enhance the pricing and allocation framework for IPOs, requiring at least 40% of shares to be allocated to book-building investors [11] - **A+H Listing Trends**: Regulatory considerations are underway to increase the minimum market capitalization requirement for A-share companies seeking to list in Hong Kong from 10 billion to 20 billion RMB [12]

厦门大学火炬创业成长营暨南强创业营是厦门大学与厦门火炬高新区联合打造的面向高校科研团队、早中期硬科技团队，选拔培育优秀科技型创业公司与 项目，深度链接科技、人才、资本、资源，提供公益创业辅导，聚焦创业实战的创业培训。 2025厦门大学火炬创业成长营暨南强创业营，一直以支持早中期硬科技项目为目标，特别关注先进制造、新能源、新材料、生物医药医疗、智能传感半导 体、电子信息等领域。 自5月正式启动项目招募以来，【2025厦大火炬创业成长营】吸引百余个硬科技项目报名，经过专家团队层层筛选，严格把关，最终苏州赛区20个项目入 围。 7月25日，2025年厦大火炬创业成长营暨南强创业营路演选拔第一站在北京圆满完成，引起京津冀地区创业者的热烈反响。路演活动落下帷幕后，参与展 示的企业与到场投资机构趁热打铁，围绕项目潜力、合作模式等内容展开了更深入的洽谈。现场互动频繁，讨论氛围热烈。 ▲北京赛区路演选拔 苏州素有 "江南水乡、智造强市" 的盛誉，集聚了众多顶尖科研院所和高新技术企业，诞生了大量前沿科技创新成果和标杆性创业项目。 8月8日，【2025厦门大学火炬创业成长营暨南强创业营】苏州赛区路演选拔，将在苏州日航酒店举办，期 ...

恒指上周连跌4个交易日，全周跌881点或3.5%，大型银行股业绩表现及美国息口走向，成为影响大市 波动的主要因素。摩根资产管理环球市场策略师周奂彤预期，港股踏入8月，或会出现短暂整固，大型 股业绩表现将成为关键。她认为，市场对降息预测持续变化，短期或影响股市，但即使美联储推迟至12 月才降息，亦是证明美国经济可以避免衰退，缓解长期压力，对风险资产属有利因素。预期美联储议息 过后，大型板块股份业绩将成为焦点，人工智能(AI)相关的科技股会继续成为重点。 她还表示，会看好亚洲的人工智能行业受惠DEEPSEEK崛起，甚至现时电动车和低空经济也有用上AI 概念。中国内地及香港相关股份现时估值合理，也有政策支持，未来有增长机会。 此外，她提到近期更多海外投资者关心中国内地及香港股市，指内地消费模式改变，利好离岸中概股， 当中以电动车、手机及出行相关板块最有机会崛起。生物科技板块近期持续抽升，她指随着欧美大企业 有兴趣与内地生科公司合作，料行业会受惠内地品牌走向国际的主题，也是看好中国内地及香港股市中 长线走势的原因之一。 ...

Group 1 - The Hang Seng Index closed up 0.49% while the ChiNext Index rose by 0.93% [1] - Zhongke Shengtai saw a significant increase, rising over 40% [1]

| | | | 2025全球独角兽榜江苏上榜企业排行榜 | | | | | --- | --- | --- | --- | --- | --- | --- | | 排名 | 全榜单排名 | 公司名称 | 估值(人民币) | 掌门人/联合创始人 | 行业 | 城市 | | l | 96 | 京东产发 | 550 | 曹冬 | 物流 | 宿迁 | | 2 | 123 | 峰巢能源 | 460 | 杨红新 | 新能源 | 常外 | | 3 | 259 | 艾博生物 | 270 | 英博 | 生物科技 | 苏州 | | 4 | 331 | 先导电科 | 220 | 朱世会 | 新材料 | 徐州 | | 5 | 384 | 清陶能源 | 210 | 南策文、李峥、何向明 | 新能源 | 苏州 | | 6 | 395 | 追觉科技 | 205 | 前浩 | 消费品 | 赤州 | | 6 | 395 | T3出行 | 205 | 崔大勇 | 共享经济 | 南京 | | 6 | 395 | 辰瑞光学 | 205 | 段匀健 | 光学电子 | 常州 | | 6 | 395 | 盛合晶微 | 205 | 崔东 | 半导体 | 无 ...

Core Viewpoint - Genting New Year (01952) has announced a subscription for 15.8462 million American Depositary Shares (ADS) of I-Mab at a price of $1.95 per ADS, totaling approximately $30.9 million, which will result in a 16.1% ownership stake in I-Mab post-transaction [1][2] Group 1 - Genting New Year shares rose over 3% and were trading at HKD 63.5 with a transaction volume of HKD 147 million at the time of reporting [1] - The subscription price of $1.95 per ADS is equivalent to approximately HKD 15.3 per ADS [1] - The total consideration for the subscription amounts to approximately HKD 243 million [1] Group 2 - I-Mab is a global biotechnology company based in the United States, focusing on developing precision immuno-oncology drugs for cancer treatment [1] - I-Mab currently has three clinical-stage pipeline products: Givastomig, Ragistomig, and Uliledlimab [1] - The board believes that the subscription will confirm I-Mab's unique capabilities in clinical translation, particularly in the U.S., and will complement Genting New Year's strong influence in Asia [2]

艾博生物估值最高达270亿元，位居榜首。清陶能源、追觅科技排名第二和第三，估值分别为210亿元、205亿元。天兵科技、镁伽估值超百亿。 | | | | 2025全球独角兽榜苏州上榜企业排行榜 | | | | --- | --- | --- | --- | --- | --- | | 排名 | 全榜单排名 | 公司名称 | 掌门人/联合创始人 | 估值(人民币) | 行业 | | l | 259 | 艾博生物 | 英博 | 270 | 生物科技 | | 2 | 384 | 清陶能源 | 南策文、李峥、何向明 | 210 | 新能源 | | 3 | 395 | 追觉科技 | 前浩 | 205 | 消费品 | | র্ব | 487 | 天兵科技 | 康永来、岁数 | 180 | 航天 | | 5 | 898 | 镁伽 | 黄瑜清 | 105 | 人工智能 | | 6 | 058 | 九识智能 | 孔旗 | 95 | 人工智能 | | 7 | 1028 | 信念医药 | 肖啸 | 90 | 生物科技 | | 8 | 1104 | 思必驰 | 、高始兴、俞凯十六六日 | 80 | 人工智能 | | 8 | 1104 ...

Core Viewpoint - Deshi Biotechnology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Huatai International as the sole sponsor, indicating a significant step towards public offering and potential growth in valuation [2]. Company Structure and Ownership - The founder, Song Ning, holds a direct stake of 30.04% and, through various investment platforms, controls a total of 52.06% voting rights, maintaining a dominant position as the controlling shareholder [2]. - The company was established in September 2016 with a registered capital of 1 million yuan, initially owned by Song Ning (90%) and his father (10%) [6]. - Over the years, Song Ning's direct shareholding has fluctuated, with a notable decrease to 47.95% after a capital increase in April 2019, but he later repurchased shares to increase his stake to 57.26% [6]. Investment and Valuation - Deshi Biotechnology has attracted multiple rounds of investment from various investors, with a post-investment valuation projected to reach 2.56 billion yuan by June 2025 [2]. - The company has undergone several capital increases, including a 15.56% stake acquisition by Hangzhou Zicheng in December 2016 and a 1.5 million yuan investment from Yuhang Industrial Fund in April 2019 [6][7]. Share Transfer and Control - The share transfer dynamics indicate that Song Ning has consistently retained control over the company, even as his direct ownership percentage has varied [4]. - Notably, the Yuhang Industrial Fund transferred a 5.24% stake back to Song Ning in April 2022 for 1.5 million yuan, further consolidating his control [7].

龙华区福城南产业片区土地整备利益统筹项目的148户住宅回迁业主喜选"新家"。 受访者供图 8月2日，深圳龙华区福城南产业片区土地整备利益统筹项目的148户住宅回迁业主迎来喜选"新家"的吉 庆时刻，这也是龙华区首个完成回迁住宅安置选房的重大土地整备项目结出民生硕果。2025年上半年， 龙华区强力推进土地整备工作，完成土地整备入库70.4公顷，所有地块均已完成权属验收及现状验收入 库。在产业、居住、民生三项关键用地类型的年度考核任务完成率上，龙华区拔得头筹，位居全市第 一，为区域高质量发展提供坚实的空间保障。 项目位于福城街道核心区域 提供508套回迁住宅 8月2日上午，龙华区福城南产业片区土地整备利益统筹项目回迁房住宅安置房选房活动举行。活动由龙 华区委区政府主导、区属国企深圳市龙华建设发展集团有限公司(以下简称"龙华建设集团")组织保障。 现场全体回迁业主顺利选定期盼已久的新居，这标志着龙华区首个完成回迁住宅安置选房的重大土地整 备项目结出民生硕果，生动诠释了国资国企"护航民生、值得信赖"的责任担当。 本批选房的项目位于福城南留用地12-04-02地块福城境未来家园，合计提供508套优质回迁住宅，包括 77平 ...